Phase II trial of 4′ deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma
Copyright policy )Phase II trial of 4′ deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma
A phase II trial of 4' Deoxydoxorubicin (DXDX) was conducted in unresectable previously untreated non-small cell lung cancer patients. DXDX was administered every 3 weeks by short intravenous infusion at a starting dose of 30 mg/m2, with dose escalation to 40 mg/m2 toxicity permitting. Four responses, all partial, were observed in 35 evaluable patients, for a response rate of 11% (95% confidence limits 3.2% and 26.7%). Myelosuppression was the dose-limiting toxicity. Cardiotoxicity was not seen. DXDX has minimal activity against non-small cell lung cancer as a single agent at the dosage used in this study.
- University of Illinois at Chicago United States
- Rush University Medical Center United States
- Northwestern University United States
Adult, Antibiotics, Antineoplastic, Lung Neoplasms, Middle Aged, Carcinoma, Bronchogenic, Doxorubicin, Carcinoma, Non-Small-Cell Lung, Drug Evaluation, Humans, Multicenter Studies as Topic
Adult, Antibiotics, Antineoplastic, Lung Neoplasms, Middle Aged, Carcinoma, Bronchogenic, Doxorubicin, Carcinoma, Non-Small-Cell Lung, Drug Evaluation, Humans, Multicenter Studies as Topic
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).5 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!